CliffBio
small molecule

DOXY-SLEEP-AID

DOXYLAMINE SUCCINATE

Loss of exclusivity—loss of exclusivity
CompanyPar →See this company's full patent-cliff portfolio

Drug detail

Brand nameDOXY-SLEEP-AID
Active ingredientDOXYLAMINE SUCCINATE
Strength25MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalJuly 1987
Marketing statusDISCN

More from Par

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

DOXY-SLEEP-AID patent cliff — loss of exclusivity — | CliffBio